Erez Chimovits bought $35M of BRVE
director, owner at Braveheart Bio, Inc.. 1,940,000 shares at an average of $18.00, traded Aug 7, 2026, filed Aug 11, 2026.
Score components
- +15RoleDirector
- +25Trade size$34.9M at market
- +3Relative to holdingsHoldings up 19%
- 0Price contextNo price history yet
- +15Cluster10 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-26-000783, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | CConversion Common Stockindirect: See footnotes | +9,132,420 | - | - | 10,235,159 | Aug 11, 2026 |
| Aug 7, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +1,666,667 | $18.00 | $30M | 11,901,826 | Aug 11, 2026 |
| Aug 7, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +273,333 | $18.00 | $4.9M | 273,333 | Aug 11, 2026 |
| Aug 7, 2026 | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -40,000,000 | $0.00 | $0 | 0 | Aug 11, 2026 |
Related signals
Other insiders at Braveheart Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Braveheart Bio, Inc. | AH Bio Fund IV, L.P. owner | $20M 1,100,000 shares | +12% | |
| 53Moderate | Braveheart Bio, Inc. | Orbimed Advisors LLC director, owner | $35M 1,940,000 shares | +19% | |
| 25Weak | Braveheart Bio, Inc. | Michele A. Anderson Chief Development Officer | $20k 1,111 shares | +0% | |
| 53Moderate | Braveheart Bio, Inc. | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | $65M 3,600,000 shares | +37% | |
| 63Notable | Braveheart Bio, Inc. | David Charles Lubner director | $1000k 55,555 shares | - | |
| 65Notable | Braveheart Bio, Inc. | Travis Murdoch CEO and President | $1.5M 83,333 shares | +3% | |
| 33Weak | Braveheart Bio, Inc. | David I Malek director | $75k 4,166 shares | +1% | |
| 58Moderate | Braveheart Bio, Inc. | Christopher Viehbacher director | $1.5M 83,333 shares | +16% | |
| 58Moderate | Braveheart Bio, Inc. | James Paul Rickey Chief Financial Officer | $500k 27,777 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.